Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 200 of 494 entries
View as:

Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke

Phase: N/A Priority: Normal
NCT ID: NCT01955707 Org: User:
Start: 01/31/14 End: 04/30/15 Due: 04/30/16

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112

Phase: N/A Priority: Normal
NCT ID: NCT03116113 Org: User:
Start: 03/08/17 End: 11/18/20 Due: 11/18/21

Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03056729 Org: User:
Start: 02/17/17 End: 03/03/20 Due: 03/03/21

Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT02332798 Org: User:
Start: 01/06/15 End: 04/15/15 Due: 04/15/16

A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities

Phase: N/A Priority: Normal
NCT ID: NCT03639987 Org: User:
Start: 12/20/18 End: 07/30/19 Due: 07/30/20

Study to Evaluate DNL151 in Subjects With Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT04056689 Org: User:
Start: 07/23/19 End: 12/02/20 Due: 12/02/21

Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)

Phase: N/A Priority: Normal
NCT ID: NCT00046488 Org: User:
Start: 09/30/02 End: 03/31/10 Due: 03/31/11

First-in-Human Study of PF-04958242 in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01159483 Org: User:
Start: 07/15/10 End: 10/16/10 Due: 10/16/11

Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02551497 Org: User:
Start: 04/30/15 End: 08/26/16 Due: 08/26/17

A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

Phase: N/A Priority: Normal
NCT ID: NCT05348785 Org: User:
Start: 04/19/22 End: 12/15/25 Due: 12/15/26

A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old

Phase: N/A Priority: Normal
NCT ID: NCT06953583 Org: User:
Start: 06/09/25 End: 11/22/29 Due: 11/22/30

Natalizumab Re-Initiation of Dosing

Phase: N/A Priority: Normal
NCT ID: NCT00306592 Org: User:
Start: 03/31/06 End: 02/29/08 Due: 02/28/09

MS PATHS Normative Sub-Study

Phase: N/A Priority: Normal
NCT ID: NCT02996084 Org: User:
Start: 12/12/17 End: 12/31/22 Due: 12/31/23

Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00810836 Org: User:
Start: 12/31/08 End: 03/31/10 Due: 03/31/11

A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration

Phase: N/A Priority: Normal
NCT ID: NCT03689972 Org: User:
Start: 11/27/18 End: 07/24/23 Due: 07/24/24

Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke

Phase: N/A Priority: Normal
NCT ID: NCT02730455 Org: User:
Start: 07/18/16 End: 11/20/17 Due: 11/20/18

Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00442780 Org: User:
Start: 08/31/07 End: 12/31/08 Due: 12/31/09

BIIB014 Cardiovascular Monitoring Study

Phase: N/A Priority: Normal
NCT ID: NCT01035515 Org: User:
Start: 12/31/09 End: 04/30/10 Due: 04/30/11

An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy

Phase: N/A Priority: Normal
NCT ID: NCT01703988 Org: User:
Start: 10/31/12 End: 01/31/15 Due: 01/31/16

BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT01156311 Org: User:
Start: 06/30/10 End: 03/31/12 Due: 03/31/13

A Single-blinded, Controlled, Multi-centre Study of Effects of Exercise in Participants With Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT01065090 Org: User:
Start: 06/30/10 End: 01/31/14 Due: 01/31/15

Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00097760 Org: User:
Start: 06/30/03 End: 03/31/04 Due: 03/31/05

Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01610310 Org: User:
Start: 06/30/12 End: 10/31/12 Due: 10/31/13

BIIB014 Effects on the Pharmacokinetics (PK) of Rosiglitazone, Warfarin, and Midazolam

Phase: N/A Priority: Normal
NCT ID: NCT01017666 Org: User:
Start: 11/01/09 End: 06/02/10 Due: 06/02/11

Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01407406 Org: User:
Start: 09/30/11 End: 02/29/12 Due: 02/28/13